News & Updates

A red magnifying glass.

High-dose PPI use among cirrhotic patients poses risk of death, complications

High-dose PPI use among cirrhotic patients poses risk of death, complications

Patients with cirrhosis who are exposed to high-dose proton pump inhibitors (PPIs) are at increased risk of death and cirrhotic complications, as suggested in a retrospective study.

High-dose PPI use among cirrhotic patients poses risk of death, complications

Which factors predict mortality in advanced HCC?

Which factors predict mortality in advanced HCC?

A study has found the high bilirubin, pretreatment hypoalbuminemia, and biochemical tests indicative of hepatic or renal dysfunctions are independently associated with short-term mortality in patients with advanced hepatocellular cancer (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev).

Which factors predict mortality in advanced HCC?

01 Mar 2024

Hepatitis E vaccine offers durable protection

Hepatitis E vaccine offers durable protection

Vaccination against hepatitis E appears to provide up to 10 years of protection, with vaccine-induced antibodies persisting for at least 8.5 years, as shown in a study from China.

Hepatitis E vaccine offers durable protection

Hypercholesterolemia linked to poor prognosis in primary biliary cholangitis

Hypercholesterolemia linked to poor prognosis in primary biliary cholangitis

In patients with primary biliary cholangitis (PBC), elevated total cholesterol levels are associated with dysregulation of lipid metabolism and may lead to poor clinical outcomes, as shown in a study.

Hypercholesterolemia linked to poor prognosis in primary biliary cholangitis

High levels of salt added to food up CKD risk

High levels of salt added to food up CKD risk

Frequently adding salt to food significantly increases the risk of chronic kidney disease (CKD) in the general population, according to a recent study.

High levels of salt added to food up CKD risk

Alcohol abstinence boosts overall survival in alcohol-associated cirrhosis

Alcohol abstinence boosts overall survival in alcohol-associated cirrhosis

Abstinence from alcohol may dramatically increase survival rates for individuals with alcohol-related cirrhosis, as reported in a study.

Alcohol abstinence boosts overall survival in alcohol-associated cirrhosis

Dietary niacin may protect against death in NAFLD

Dietary niacin may protect against death in NAFLD

Dietary niacin intake may benefit individuals with nonalcoholic fatty liver disease (NAFLD), with a study suggesting that a higher intake lowers the risk of mortality.

Dietary niacin may protect against death in NAFLD

13 Feb 2024

Immunotherapy, TACE-based regimen may reshape HCC treatment landscape

Immunotherapy, TACE-based regimen may reshape HCC treatment landscape

In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.

Immunotherapy, TACE-based regimen may reshape HCC treatment landscape

13 Feb 2024

Use of radioligand therapy in a patient with metastatic GEP-NET

Use of radioligand therapy in a patient with metastatic GEP-NET

A 64-year-old male with good past health presented in March 2019 with 2 days’ history of abdominal pain, which subsided on its own.

Use of radioligand therapy in a patient with metastatic GEP-NET

Larsucosterol for hepatitis proves safety in phase IIa trial

Larsucosterol for hepatitis proves safety in phase IIa trial

Treatment with larsucosterol is safe and well tolerated in patients with alcohol-associated hepatitis (AH), as shown in a recent study.

Larsucosterol for hepatitis proves safety in phase IIa trial

01 Feb 2024

Something went wrong.